Supriya Peshin, Visiting Resident in Hematology and Oncology at MD Anderson Cancer Center, shared a post on X:
“Learned something new today in GI Oncclinic MD Anderson Cancer Center: FDA approved retifanlimab +carboplatin/paclitaxel for first-line treatment of advanced SCAC major step forward in care for Anal cancer.”
Read Full Blog on FDA.
Read More on OncoDaily’s special article: “FDA Approves Retifanlimab-dlwr with Chemotherapy and as Monotherapy for Advanced Squamous Cell Carcinoma of the Anal Canal”
